Merck's KEYTRUDA (pembrolizumab) + Padcev for Perioperative muscle-invasive bladder cancer (sBLA) — FDA decision expected August 17, 2026.
Run-up into the PDUFA
Daily close so far, T-120 through today. High $6.75, low $2.91. Run-up to date -29.5%. Decision 8/17/26. Historical price action, not a forecast.
Key facts
PDUFA date2026-08-17
Business days away26
Drug / candidateKEYTRUDA (pembrolizumab) + Padcev
IndicationPerioperative muscle-invasive bladder cancer (sBLA)
CompanyMerck
Market-cap tier—
Cohort decision-day move (history)±2% median
Cohort move is the historical median absolute decision-day move for this market-cap tier — history, not a prediction. See the full 2026 PDUFA calendar →